AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.
A non-fungible token for a Nobel Prize-winning cancer immunotherapy invention has been minted ahead of an auction tomorrow arranged by the University of California, Berkeley.
Philips has settled trade secrets and copyright claims against a medical imaging company, having already survived accusations of breaching antitrust law.
AbbVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.
Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.
Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.
GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Amarin delayed the market entry of generic versions of the cardiovascular drug Vascepa by using supply agreements to halt competitors from accessing the drug’s active pharmaceutical ingredient, according to a new antitrust lawsuit.
In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.
L’Oreal has secured a victory after a US federal court ruled that the French cosmetics brand did not infringe patents owned by the University of Massachusetts because they were invalid.